Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing

Jahrsdörfer, Bernd; Kroschel, Joris; Ludwig, Carolin; Corman, Victor M.; Schwarz, Tatjana; Körper, Sixten; Rojewski, Markus; Lotfi, Ramin; Weinstock, Christof; Drosten, Christian; Seifried, Erhard; Stamminger, Thomas; Gross, Heinz; Schrezenmeier, Hubert

doi:10.1093/infdis/jiaa656

Cited by 52 publications

(79 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the large sample size, equivalent to ∼10% of the urban population of Qatar, as well as the probabilistic weighting used in the analysis may have reduced inherent biases in our sample. Laboratory methods were based on high-quality, validated commercial platforms, such as the Roche platform used for serological testing [16,31]. The Roche platform is one of the most extensively used and investigated commercial platforms, with a specificity ≥99.8% [16,32,33] and a sensitivity ≥89% [12,31,33].…”

Section: Discussionmentioning

confidence: 99%

“…Laboratory methods were based on high-quality, validated commercial platforms, such as the Roche platform used for serological testing [16,31]. The Roche platform is one of the most extensively used and investigated commercial platforms, with a specificity ≥99.8% [16,32,33] and a sensitivity ≥89% [12,31,33]. However, it is possible that the less-than-perfect sensitivity, especially for those with recent infections, may have underestimated the actual seroprevalence.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

Coyle

Chemaitelly

Kacem

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundQatar has experienced a large SARS-CoV-2 epidemic. Our first objective was to assess the proportion of the urban population that has been infected with SARS-CoV-2, by measuring the prevalence of detectable antibodies. Our second objective was to identify predictors for infection and for having higher antibody titers.MethodsResidual blood specimens from individuals receiving routine and other clinical care between May 12-September 9, 2020 were tested for anti-SARS-CoV-2 antibodies. Associations with seropositivity and higher antibody titers were identified through regression analyses. Probability weights were applied in deriving the epidemiological measures.ResultsWe tested 112,941 individuals (∼10% of Qatar’s urban population), of whom 51.6% were men and 66.0% were 20-49 years of age. Seropositivity was 13.3% (95% CI: 13.1-13.6%) and was significantly associated with sex, age, nationality, clinical-care type, and testing date. The proportion with higher antibody titers varied by age, nationality, clinical-care type, and testing date. There was a strong correlation between higher antibody titers and seroprevalence in each nationality, with a Pearson correlation coefficient of 0.85 (95% CI: 0.47-0.96), suggesting that higher antibody titers may indicate repeated exposure to the virus. The percentage of antibody-positive persons with prior PCR-confirmed diagnosis was 47.1% (95% CI: 46.1-48.2%), severity rate was 3.9% (95% CI: 3.7-4.2%), criticality rate was 1.3% (95% CI: 1.1-1.4%), and fatality rate was 0.3% (95% CI: 0.2-0.3%).ConclusionsFewer than two in every 10 individuals in Qatar’s urban population had detectable antibodies against SARS-CoV-2 between May 12-September 9, 2020, suggesting that this population is still far from the herd immunity threshold and at risk from a subsequent epidemic wave.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

Coyle

Chemaitelly

Kacem

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The laboratory methods were based on high-quality and validated commercial platforms, such as the Roche platform used for the serological testing [18, 39], one of the best available and extensively used and investigated commercial platforms with a specificity ≥99.8% [18, 40] and a sensitivity ≥95% [7, 39]. However, the less-than-perfect sensitivity may have lowered the measured antibody-positivity prevalence by a few percentage points.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar

Al-Thani¹,

Farag²,

Bertollini³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundQatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual worker (CMW) population who comprise 60% of the total population. This study aimed to assess the proportions of ever and/or current infection in this population.MethodsA cross-sectional population-based survey was conducted during July 26-September 09, 2020 to assess both anti-SARS-CoV-2 positivity through serological testing and polymerase chain reaction (PCR) positivity through PCR testing. Associations with antibody and PCR positivity were identified through regression analyses.ResultsStudy included 2,641 participants, 69.3% of whom were <40 years of age. Anti-SARS-CoV-2 positivity was estimated at 55.3% (95% CI: 53.3-57.3%) and was significantly associated with nationality, geographic location, educational attainment, occupation, presence of symptoms in the two weeks preceding the survey, and previous infection diagnosis. PCR positivity was assessed at 11.3% (95% CI: 9.9-12.8%) and was significantly associated with geographic location, contact with an infected person, and reporting two or more symptoms. Infection positivity (antibody and/or PCR positive) was assessed at 60.6% (95% CI: 9.9-12.8%). The proportion of antibody-positive CMWs that had a prior SARS-CoV-2 diagnosis was 9.3% (95% CI: 7.9-11.0%). Only seven infections were ever severe and one was ever critical—an infection severity rate of 0.5% (95% CI: 0.2-1.0%).ConclusionsSix in every 10 CMWs have been infected, suggestive of reaching the herd immunity threshold. Infection severity was low with only one in every 200 infections progressing to be severe or critical. Only one in every 10 infections had been previously diagnosed suggestive of mostly asymptomatic or minimally mild infections.

show abstract

“…The Roche assay was the weaker predictor of neutralizing capacity (r=0.56, p=0.0001) compared to the Abbott assay (NCP IgG) (r=0.69, p<0.0001), Siemens assay (RDB total antibodies) (r=0.74, p<0.001), and the S1/S2-based DiaSorin assay (S1/S2 IgG ) (r=0.84, p<0.0001) [17]. Jahrsdörfer et al and Padoan et al confirm that the weaker correlation was observed using the Roche assay [11,22], and McAndrews et al found that 86% of individuals positive for RBD-directed antibodies exhibited neutralizing capacity, whereas only 76% of positive NCP-directed antibodies exhibited neutralizing capacity [23]. The fact that anti-NCP assays have the lowest neutralizing capacity could be expected, as neutralizing antibodies are directed to the spike protein responsible for enabling cell entry.…”

Section: To the Editormentioning

confidence: 91%

“…0.128) [9]. The specificity of the test was excellent in several independent evaluations (99.8-100%) [8][9][10][11]. The RT-PCR for SARS-CoV-2 determination in respiratory samples (nasopharyngeal swab samples) was performed on the LightCycler® 480 Instrument II (Roche Diagnostics®) using the LightMix® Modular SARS-CoV E-gene set.…”

Section: To the Editormentioning

confidence: 99%

Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients

Favresse

Elsen

Eucher

et al. 2020

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing

Cited by 52 publications

References 10 publications

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar

Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients

Contact Info

Product

Resources

About